Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030


Dolomite Market Growth & Trends

The global dolomite market size is expected to reach USD 3.05 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising investments in wastewater treatment plants along with expansion in steel production are expected to propel the consumption of dolomite across the forecast period.

Dolomite is a mineral consisting of carbonates of calcium & magnesium and other impurities. Based on product, the market is segmented into calcined, sintered, and agglomerated dolomite. The agglomerated segment accounted for a revenue share of over 29.0% in 2022 of the overall market. It is witnessing high demand from industries such as construction, agriculture, glass, magnesite, animal feed, and others, as it has high calcium carbonate content. It can also be processed into dololime which can be further processed into precipitated calcium carbonate (PCC) products.

Based on end-use, the market is segmented into iron & steel, construction, glass & ceramics, agriculture, water treatment, and others. Water treatment is anticipated to register high growth over the forecast period. Dolomite is used in wastewater treatment plants to balance the acidity and alkalinity of the water. Its usage helps remove excess salts and heavy metals from the water, making it safe for discharge into the environment. By doing this, dolomite helps make the water treatment process more effective and efficient.

Based on region, North America is expected to grow at a CAGR of 6.9% over the forecast period. The consumption of dolomite in the region is increasing due to the growing developments in the construction industry and massive steel production. The U.S. is the largest dolomite industry in the region. According to IEA, the U.S. contributes over 70% to the crude steel production of North America.

The dolomite industry is highly competitive owing to the presence of several producers. They face competition from other manufacturers engaged in producing substitutes like limestone and ilmenite. As a result, they adopt strategic initiatives like capacity expansion and mergers & acquisitions to stay ahead of the competition. For instance, in March 2023, ?i?ecam invested in the expansion of its sand separation facility and limestone and dolomite processing facility in Mersin, Turkey to ensure a consistent raw material supply for its flat glass production.

Dolomite Market Report Highlights
  • Calcined products held a market share of over 39.0% in 2024.This material is commonly used as a refractory material in the manufacturing of basic refractories.
  • Iron & Steel segment held a market share of over 60.0% in 2024.The product is utilized as a refractory material in steelmaking processes such as converter lining, opening hearth furnaces, and electric furnace walls.
  • North America dolomite market held over 36.0% revenue share of the global market. The North America dolomite market is expected to sustain its dominance owing to its extensive demand for dolomite in the construction industry.
  • The Asia Pacific dolomite market is anticipated to register the fastest growth over the forecast period. The region is witnessing expansion in steel facilities.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Tumor Type
1.2.2. Model Type
1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Patient-derived Xenograft Model Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Burden of Cancer Across the Globe
3.2.1.2. Increasing R&D Investment for Cancer Research
3.2.1.3. Demand for Personalized Therapies Worldwide
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost of Personalized PDX Models
3.2.2.2. Stringent Regulations Towards the Use of Animal Models
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Patient-derived Xenograft Model Market: Tumor Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Patient-derived Xenograft Model Market; Tumor Type Movement Analysis
4.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Tumor Type, 2018 to 2030 (USD Million)
4.4. Lung Cancer
4.4.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Pancreatic Cancer
4.5.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Prostate Cancer
4.6.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Breast Cancer
4.7.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Patient-derived Xenograft Model Market: Model Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Patient-derived Xenograft Model Market; Model Type Movement Analysis
5.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by Model Type, 2018 to 2030 (USD Million)
5.4. Mice Model
5.4.1. Mice model market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Rat Model
5.5.1. Rat model market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Patient-derived Xenograft Model Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Patient-derived Xenograft Model Market; End Use Movement Analysis
6.3. Global Patient-derived Xenograft Model Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical and Biopharmaceutical Companies
6.4.1. Pharmaceutical and biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Academic and Research Institutes
6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
6.6. CRO’s and CDMO’s
6.6.1. CRO’s and CDMO’s market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Patient-derived Xenograft Model Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. North America
7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Competitive scenario
7.3.2.3. Regulatory framework
7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Competitive scenario
7.3.3.3. Regulatory framework
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Competitive scenario
7.3.4.3. Regulatory framework
7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory framework
7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory framework
7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Denmark
7.4.7.1. Key country dynamics
7.4.7.2. Competitive scenario
7.4.7.3. Regulatory framework
7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key country dynamics
7.4.8.2. Competitive scenario
7.4.8.3. Regulatory framework
7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.9. Norway
7.4.9.1. Key country dynamics
7.4.9.2. Competitive scenario
7.4.9.3. Regulatory framework
7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. China
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.7. Thailand
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Regulatory framework
7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Regulatory framework
7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. South Africa
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Competitive scenario
7.7.4.3. Regulatory framework
7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Competitive scenario
7.7.5.3. Regulatory framework
7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Company Market Position Analysis, 2024
8.3. Company Profiles
8.3.1. Charles River Laboratories
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Service benchmarking
8.3.1.4. Strategic initiatives
8.3.2. The Jackson Laboratory
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Service benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Crown Bioscience
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Service benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Altogen Labs
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Service benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Envigo
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Service benchmarking
8.3.5.4. Strategic initiatives
8.3.6. WuXi AppTec
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Service benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Oncodesign
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Service benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hera Biolabs
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Service benchmarking
8.3.8.4. Strategic initiatives
8.3.9. XenTech
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Service benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Abnova Corp.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Service benchmarking
8.3.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings